Dow Jones
40.576,74 -160,22 (-0,39%) Nasdaq
17.169,71 +143,83 (+0,84%) Nikkei 225
35.619,77 -539,39 (-1,49%) EUR/USD
1,1020 -0,0002 (-0,02%) Bitcoin EUR
52.373,10 +482,70 (+0,93%) XRP EUR
0,49 -0,00 (-0,58%)
Roche Holding AG (RHHVF)
| Chiusura precedente | 327,00 |
| Aperto | 306,00 |
| Denaro | 299,50 x 4000 |
| Domanda | 323,52 x 3100 |
| Min-Max giorno | 299,50 - 311,80 |
| Intervallo di 52 settimane | 233,12 - 340,88 |
| Volume | |
| Media Volume | 9.306 |
| Capitalizzazione | 242,335B |
| Beta (mensile su 5 anni) | 0,15 |
| Rapporto PE (ttm) | 19,11 |
| EPS (ttm) | 15,67 |
| Prossima data utili | 25 lug 2024 |
| Rendimento e dividendo (futuro) | 10,86 (3,45%) |
| Data ex dividendo | 14 mar 2024 |
| Stima target 1A | N/D |
GlobeNewswireLate-breaking data for Roche’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS) More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeks The safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to date B
- GlobeNewswire
New data for Roche’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
10-year efficacy data highlight OCREVUS’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS contr
- GlobeNewswire
Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeks OCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutane
